Bristol Myers Squibb stock stays anchored by revenue and earnings

Bristol Myers Squibb stock is anchored by $11.4 billion in second-quarter 2026 revenue and $1.46 in adjusted EPS. The company reported the figures on 31 July 2026 and kept its 2026 revenue outlook at roughly $46.5 billion.

Bristol Myers Squibb (US0897961004) stock is anchored by $11.4 billion in second-quarter 2026 revenue and $1.46 in adjusted EPS. The company reported those figures on 31 July 2026 and kept its 2026 revenue outlook at roughly $46.5 billion.

Revenue and EPS hold the line

For the quarter ended 30 June 2026, Bristol Myers Squibb reported revenue of $11.4 billion, while adjusted earnings per share came in at $1.46. The company also said its adjusted EPS for the same period reached $1.46, giving investors a clean earnings reference point for the first half of the year.

The comparison matters: full-year 2026 revenue guidance of about $46.5 billion implies the second quarter accounted for roughly one quarter of the annual target. That framing puts the quarter in context even without a dramatic market rerating attached to the result.

$46.5 billion outlook

The 2026 revenue outlook of about $46.5 billion is the key forward marker in the latest report. Bristol Myers Squibb also kept the metric tied to an expected period of execution rather than a one-off quarter, which makes guidance more important than a single headline number.

In the same report, the company highlighted second-quarter 2026 performance against a backdrop of continued portfolio management and capital allocation. For investors, the combination of $11.4 billion in quarterly sales and $1.46 in adjusted EPS is the cleanest read-through.

Opdivo remains important

Opdivo remains one of the company’s best-known products and still matters to the revenue mix. Bristol Myers Squibb has used its oncology and immunology portfolio to support the business while the market watches how the main products contribute to the 2026 outlook.

The report’s central message is numerical rather than narrative: $11.4 billion in quarterly revenue, $1.46 in adjusted EPS, and about $46.5 billion in full-year revenue guidance. That is enough to define the stock’s current baseline for the second half of 2026.

Shares and valuation context

Bristol Myers Squibb stock is listed on the NYSE under ticker BMY and belongs to the pharmaceuticals group within health care. The company’s market capitalization, the share price as of 9 August 2026, and the next earnings date were not evidenced in the available search results, so they are omitted here.

The practical takeaway is that the latest quarter gives the stock a dated earnings anchor, not a price target story. The focus remains on revenue, adjusted EPS, and the 2026 guide rather than on a fresh rating move.

Company facts

• Company: Bristol Myers Squibb Company
• ISIN: US0897961004
• Ticker: NYSE: BMY
• Trading venue: NYSE
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500